Elanco Animal Health (NYSE:ELAN) Issues Q2 2025 Earnings Guidance

Elanco Animal Health (NYSE:ELAN - Get Free Report) issued an update on its second quarter 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.170-0.210 for the period, compared to the consensus estimate of 0.200. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion.

Elanco Animal Health Trading Up 0.1%

Elanco Animal Health stock traded up $0.02 during trading on Friday, reaching $14.32. The company had a trading volume of 5,611,213 shares, compared to its average volume of 5,164,207. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.46 and a current ratio of 2.71. Elanco Animal Health has a 12-month low of $8.02 and a 12-month high of $15.78. The stock's 50 day moving average price is $12.39 and its two-hundred day moving average price is $11.51. The firm has a market capitalization of $7.11 billion, a price-to-earnings ratio of 19.34, a PEG ratio of 2.80 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.06. Elanco Animal Health had a net margin of 8.43% and a return on equity of 7.54%. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the previous year, the firm earned $0.34 earnings per share. Elanco Animal Health's revenue for the quarter was down 1.0% on a year-over-year basis. As a group, equities analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. William Blair upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research note on Thursday. Stifel Nicolaus boosted their price objective on shares of Elanco Animal Health from $15.00 to $16.00 and gave the stock a "buy" rating in a research note on Monday, May 19th. Finally, Piper Sandler reduced their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research report on Thursday, March 6th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $15.17.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its position in shares of Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company's stock worth $50,268,000 after purchasing an additional 2,445,872 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Elanco Animal Health by 4.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company's stock valued at $18,830,000 after acquiring an additional 76,408 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Elanco Animal Health in the first quarter valued at $2,065,000. Finally, Empowered Funds LLC raised its holdings in Elanco Animal Health by 35.2% in the first quarter. Empowered Funds LLC now owns 15,835 shares of the company's stock valued at $166,000 after acquiring an additional 4,121 shares in the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.